K. Bogman

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
K Bogman, Katrijn Bogman
Publication record
20 papers · 866 citations · H-index 11

PAPERS

Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data
20251 citationsauthor #4
CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy
20242 citationsauthor #5
Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema
20249 citationsauthor #11
Ocular Pharmacokinetics of Faricimab Following Intravitreal Administration in Patients With Retinal Disease
20246 citationsauthor #6
Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials
20193 citationsauthor #1
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
20180 citationsauthor #8
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects
201712 citationsauthor #8
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects
201746 citationsauthor #6
Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib
201741 citationsauthor #5
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
201736 citationsauthor #2
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects
201755 citationsauthor #3
Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population.
201618 citationsauthor #4
Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)
201680 citationsauthor #1
Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram (ECG) monitoring of alectinib phase I/II pivotal studies.
20160 citationsauthor #2
Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
20109 citationsauthor #1
Mechanisms of Venoocclusive Disease Resulting From the Combination of Cyclophosphamide and Roxithromycin
20065 citationsauthor #5
P‐Glycoprotein and Surfactants: Effect on Intestinal Talinolol Absorption
2005121 citationsauthor #1
The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins.
2003178 citationsauthor #1
Transport of amentoflavone across the blood-brain barrier in vitro.
200246 citationsauthor #4
HMG‐CoA reductase inhibitors and P‐glycoprotein modulation
2001198 citationsauthor #1

TIMELINE

2001 198 citations

2002 46 citations

2003 178 citations

2005 121 citations

2006 5 citations

2010 9 citations

2016 98 citations

2017 190 citations

2018 0 citations

2019 3 citations

2024 17 citations

2025 1 citations

K. Bogman

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT